COVID-related fibrosis: insights into potential drug targets.
Giacomo SgallaAlessia ComesMarialessia LeredeLuca RicheldiPublished in: Expert opinion on investigational drugs (2021)
Despite the strong rationale support the use of antifibrotic therapies in COVID-related fibrosis, there are several uncertainties regarding the timing for their introduction and the real risks/benefits ratio of antifibrotic treatment in the acute and the chronic phases of the disease. The findings of ongoing clinical trials and the long-term observation of longitudinal cohorts will eventually clarify the best management approach for these patients.
Keyphrases
- coronavirus disease
- clinical trial
- sars cov
- end stage renal disease
- drug induced
- ejection fraction
- newly diagnosed
- chronic kidney disease
- human health
- liver failure
- randomized controlled trial
- respiratory failure
- pulmonary fibrosis
- climate change
- cross sectional
- intensive care unit
- hepatitis b virus
- open label
- mechanical ventilation
- study protocol